Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK.
PMID: 27742812
2017
The Journal of antimicrobial chemotherapy
Abstract: The most common mutations detected at >20% and 2%-20% mutation frequency differed for each drug class, these respectively being: L90M (n = 7) and M46IL (n = 10) for PIs; T215rev (n = 9) and D67GN (n = 4) for NRTIs; and K103N (n = 5) and G190E (n = 2) for NNRTIs.
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.
Abstract: The most frequently detected TDRMs were K103N (2.2%), T215 revertants (1.6%), M41L (0.9%) and L90M (0.7%).
Result: The most frequently detected mutations were T215 revertants (not F/Y) (268; 1.6%) and other TAMs [M41L (141; 0.9%) and K219Q/N (104; 0.6%)] conferring resistance to the NRTI drug class; K103N (354; 2.2%) and Y181C (66; 0.4%) conferring resistance to the NNRTI drug class, and L90M (111; 0.7%) and M46L (48; 0.3%) conferring resistance to the PI drug class.
Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network.
Abstract: K103N, Y181C, and L90M) had transmission fitness that was indistinguishable from or exceeded wild-type fitness, permitting the establishment of large, self-sustaining drug resistance reservoirs.
Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
PMID: 28645089
2017
Journal of molecular graphics & modelling
Abstract: In this work, we examined the effect of non active site mutations L10F, L10F/N88S and L90M with nelfinavir using molecular dynamics simulation and binding free energy calculations.
Abstract: The simulations suggested that the L10F and L10F/N88S mutants decrease the binding affinity of nelfinavir, whereas the L90M mutant increases the binding affinity.
Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996-2012.
Abstract: PI mutations detected were M46I (n=1, 0.9%) and L90M (n=1, 0.9%).
Result: The two major PI mutations found were M46I (n = 1; 0.9%), which causes low-level resistance to nelfinavir (NFV) and L90M (n = 1; 0.9%), which causes high-level resistance to NFV, intermediate resistance to indinavir/ritonavir (IDV/r) and saquinavir/ritonavir (SQV/r) and low-level resistance to atazanavir/ritonavir (ATV/r), fosamprenavir/ritonavir (FPV/r) and lopinavir/ritonavir (LPV/r).
Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran.
PMID: 29026792
2017
Iranian journal of public health
Table: L90M
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Method: Primary PI-R substitutions assessed were D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V, V82A/F/L/S/T, I84V, N88S, and L90M in PR.
Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.
HIV mutation literature information.
PMID: 
2018
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT